Waters Corporation is projected to report Q2 2026 revenue of $745.2 million and EPS of $3.01, with the stock currently trading at $355.20 relative to a $378.50 average analyst price target. Investors are primarily focused on the recovery of Instrument Sales as a leading indicator for laboratory capital expenditure and pharmaceutical sector health.
Market participants are specifically looking for signs of stabilization in China, which has been a significant headwind for the life sciences tools industry over the past year. Furthermore, management's updated full-year 2026 guidance will be critical in determining if the current margin expansion trajectory can be sustained through the second half of the year.